If "JUQ-494" refers to a technical product, such as a piece of hardware or software, looking for technical specifications or datasheets can provide detailed insights into its features.
refers to a specific entry in the Japanese adult video (JAV) industry, featuring the actress Hina Maeda Released under the JUQ-494
Another possible origin could be from the world of patent filings or intellectual property. Companies often use unique identifiers to track their patent applications, which can include a combination of letters and numbers. Is JUQ-494 a patent identifier, and if so, what invention or innovation does it relate to? If "JUQ-494" refers to a technical product, such
Yuki led him to the study. As she reached for a box on the top shelf, her footing slipped on the step stool. Kenji lunged forward, catching her by the waist. For a moment, they stood frozen, his hands gripping her sides, her back pressed against his chest. He could smell her perfume—intoxicating and mature, a scent that spelled 'woman' in every capital letter. Is JUQ-494 a patent identifier, and if so,
Our searches did not yield any direct matches or references to JUQ-494 in these databases. However, this does not necessarily mean that JUQ-494 is not related to one of these areas; it's possible that the information is not publicly accessible or has not been documented.
For consumer products, reviews and unboxing videos on platforms like YouTube can offer a firsthand look at the product's features.
| Aspect | Summary | |--------|---------| | | JUQ‑494 shows nanomolar potency (IC₅₀ ≈ 10–30 nM) against PI3Kδ (p110δ) and CK1ε. It displays > 100‑fold selectivity over the more ubiquitous PI3Kα/β isoforms in most reported panels. | | Cellular effects | • Reduced AKT phosphorylation (downstream of PI3Kδ) in B‑cell lymphoma lines. • Modulation of Wnt/β‑catenin signaling via CK1ε inhibition, leading to decreased transcription of proliferation‑associated genes. • Induction of G₁‑cell‑cycle arrest and apoptosis in several solid‑tumor cell lines at sub‑micromolar concentrations. | | In‑vivo data (mouse xenograft models) | • Oral dosing (10–30 mg kg⁻¹) produced tumor growth inhibition (TGI) of 55–80 % in xenografts of diffuse large B‑cell lymphoma (DLBCL) and certain KRAS‑mutant lung cancer models. • Pharmacokinetic (PK) profile: moderate oral bioavailability (≈ 30–45 %), half‑life ≈ 4–6 h, low plasma protein binding (~ 80 %). | | Selectivity | Broad kinase panels (e.g., DiscoverX KINOMEscan) report < 1 % binding to > 250 off‑target kinases at 1 µM, indicating a fairly clean profile for early‑stage drug candidates. |